Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study
- 29 Downloads
To evaluate the efficacy of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for cervical esophageal cancer (CEC), we performed a retrospective analysis of CEC patients treated by DCF-RT at a single institution.
We conducted a single-center retrospective study. Twenty-one patients with CEC who underwent DCF-RT between 1999 and 2017 at our institute were included in this study. Chemotherapy consisted of intravenous docetaxel at 50 mg/m2 on day 1, intravenous CDDP at 60 mg/m2 on day 1, and intravenous 5-FU at 600 mg/m2 on days 1–4, repeated every 4 weeks for two cycles. Among the 21 patients, six were irradiated using three-dimensional conformal RT (3D- conformal RT) and 15 were treated using intensity-modulated RT (IMRT) consisting of 60 Gy in 30 fractions.
The median follow-up period was 49.6 months (range 4.6–97.6). The overall complete response (CR) and local CR rates were 61.9% and 81.0% for all patients, and 76.9% and 84.6% for patients without hypopharyngeal and/or thoracic esophageal invasion, respectively. The 3-year overall survival (OS), progression-free survival (PFS), and local failure-free survival (LFFS) rates were 79.6, 52.4, and 74.7%, respectively. Grade 3–4 leucopenia developed in 12 patients (70.6%), neutropenia developed in 13 patients (81.2%), and mucositis developed in 2 patients (9.5%). There were no treatment-related deaths.
The 3-year OS and LFFS of patients who underwent DCF-RT were higher than those in the previous studies. Although the high rate of myelosuppression requires careful management, DCF-RT is a safe and effective modality for CEC.
KeywordsCervical esophageal cancer Chemoradiotherapy DCF Prognosis
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest associated with this manuscript.
- 6.Zenda S, Kojima T, Kato K et al (2016) Multicenter phase 2 study of cisplatin and 5-fluorouracil with concurrent radiation therapy as an organ preservation approach in patients with squamous cell carcinoma of the cervical esophagus. Int J Radiat Oncol Biol Phys 96:976–984. https://doi.org/10.1016/j.ijrobp.2016.08.045 CrossRefGoogle Scholar
- 7.Ito M, Kodaira T, Tachibana H et al (2017) Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. Head Neck 39:2406–2415. https://doi.org/10.1002/hed.24909 CrossRefGoogle Scholar
- 8.Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (radiation therapy oncology Group 94-05) phase III trial of combined-Modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174. https://doi.org/10.1200/JCO.2002.20.5.1167 CrossRefGoogle Scholar
- 10.Ishida K, Ando N, Yamamoto S et al (2004) Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan esophageal oncology group (JEOG)/Japan clinical oncology group trial (JCOG9516). Jpn J Clin Oncol 34:615–619. https://doi.org/10.1093/jjco/hyh107 CrossRefGoogle Scholar
- 13.Sobin L, Gospodarowicz M WC (2009) TNM Classification of Malignant Tumours, 7th Edition. In: WileyGoogle Scholar
- 17.Katori H, Tsukuda M (2005) Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Clin Oncol 17:148–152. https://doi.org/10.1016/j.clon.2004.09.013 CrossRefGoogle Scholar
- 18.Tamaki Y, Hieda Y, Nakajima M et al (2018) Concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil improves survival of patients with advanced esophageal cancer compared with conventional concurrent chemoradiotherapy with cisplatin and 5-fluorouracil. J Cancer 9:2765–2772. https://doi.org/10.7150/jca.23456 CrossRefGoogle Scholar
- 20.Higuchi K, Komori S, Tanabe S et al (2014) Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys 89:872–879. https://doi.org/10.1016/j.ijrobp.2014.03.030 CrossRefGoogle Scholar